The combination of an oncolytic virus known as talimogene laherparepvec with ipilimumab yielded a significantly higher response rate than ipilimumab alone in a phase II study of patients with advanced melanoma.
Ahead of this year’s National Skin Cancer Action Week, MMP clinicians and researchers descended on Brisbane for a joint meeting of the 9th World Congress of Melanoma and 14th International Congress of the Society for Melanoma Research – the world’s largest congress on melanoma with over 1500 delegates from 53 countries.
Summary of her project: Melanoma, known as Australia’s national cancer, is the deadliest type of skin cancer with the highest rates being reported in Australia and New Zealand (~60 cases per 100 000 individuals per year). Locally, melanoma is also the most commonly diagnosed cancer in young Australians aged between 15 and 39 years, making up 20% of all cancer cases and killing more of these individuals than any other single cancer.
Lentigo maliga is a type of in-situ (superficial) melanoma which often presents a treatment challenge as it commonly occurs on cosmetically sensitive areas of the head and neck of elderly patients and may require several surgical procedures to achieve adequate clearance.